Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Next Previous
X
Search
Trial Profile

A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary) ; Onalespib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Colon cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer; Uterine cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 04 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2021 Results evaluating the synergism between HSP90i and PARPi in vivo by performing tolerability and efficacy studies of onalespib combined with olaparib in patient-derived xenograft (PDX) models of ovarian cancer and subsequently conducted a Phase 1 study of these agents in patients with advanced solid tumours published in the British Journal of Cancer
    • 09 Dec 2021 Planned End Date changed from 1 Dec 2021 to 8 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top